dicumarol and Hemorrhage

Topics: Adult; Anticoagulants; Blood Coagulation; Dicumarol; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Placebos; Prognosis; Time Factors

Topics: Acetylcholine; Antimetabolites; Aspirin; Autonomic Nervous System; Blood Circulation; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Platelets; Calcium; Cell Aggregation; Clot Retraction; Dicumarol; Epinephrine; Factor IX; Factor V; Factor VII; Factor VIII; Factor X; Fibrin; Fibrinogen; Hemorrhage; Hemostasis; Humans; Prothrombin; Prothrombin Time; Surgical Procedures, Operative; Thrombin; Vasoconstrictor Agents; Vasodilator Agents; Vitamin K

Topics: Adenine Nucleotides; Aminocaproates; Animals; Anticoagulants; Blood Platelets; Dicumarol; Fractures, Bone; Hemorrhage; Hemostasis; Heparin; Hip Injuries; Humans; Thromboembolism; Thrombosis

A consensus has not been reached about the optimal duration of oral anticoagulant therapy after a second episode of venous thromboembolism.. In a multicenter trial, we compared six months of oral anticoagulant therapy with anticoagulant therapy continued indefinitely in patients who had had a second episode of venous thromboembolism. Of 227 patients enrolled, 111 were randomly assigned to six months of anticoagulation and 116 were assigned to receive anticoagulant therapy indefinitely; for both groups, the target international normalized ratio was 2.0 to 2.85. The initial episodes of deep-vein thrombosis (n = 193) and pulmonary embolism (n = 34), as well as recurrent episodes, were all objectively confirmed.. After four years of follow-up, there were 26 recurrences of venous thromboembolism that fulfilled the diagnostic criteria, 23 in the group assigned to six months of therapy (20.7 percent) and 3 in the group assigned to continuing therapy (2.6 percent). The relative risk of recurrence in the group assigned to six months of therapy, as compared with the group assigned to therapy of indefinite duration, was 8.0 (95 percent confidence interval, 2.5 to 25.9). There were 13 major hemorrhages, 3 in the six-month group, (2.7 percent) and 10 in the infinite-treatment group (8.6 percent). The relative risk of major hemorrhage in the six-month group, as compared with the infinite-treatment group was 0.3 (95 percent confidence interval, 0.1 to 1.1). There was no difference in mortality between the two groups.. Prophylactic oral anticoagulation that was continued for an indefinite period after a second episode of venous thromboembolism was associated with a much lower rate of recurrence during four years of follow-up than treatment for six months. However, there was a trend toward a higher risk of major hemorrhage when anticoagulation was continued indefinitely.

Topics: Administration, Oral; Aged; Anticoagulants; Dicumarol; Female; Follow-Up Studies; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Probability; Pulmonary Embolism; Recurrence; Thrombophlebitis; Time Factors; Warfarin

Topics: Age Factors; Aged; Anticoagulants; Cerebrovascular Disorders; Clinical Trials as Topic; Diabetes Complications; Dicumarol; Electrocardiography; Female; Heart Failure; Hemorrhage; Heparin; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Phenindione; Placebos; Pulmonary Embolism; Recurrence; Sex Factors; Thrombophlebitis; Time Factors; Warfarin

Topics: Adult; Atrial Fibrillation; Cerebral Hemorrhage; Dicumarol; Ecchymosis; Embolism; Evaluation Studies as Topic; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Kidney; Long-Term Care; Male; Middle Aged; Mitral Valve Insufficiency; Mitral Valve Stenosis; Oral Hemorrhage; Uterine Hemorrhage

Bromadiolone, commonly known as super warfarin, is a long-acting coumarin dicoumarin rodenticide. The mechanism of bromadiolone is mainly to inhibit vitamin K1 epoxide reductase and affect the synthesis of coagulation factors Ⅱ, Ⅶ, Ⅸ and Ⅹ, which causes blood coagulation dysfunction and systemic multiple organ hemorrhage. Here, we report of a case of bromadiolone poisoning patient who had digestive tract, abdominal hemorrhage, as well as secondary paralytic ileus. After blood product transfusion and vitamin K1 supplementation, the patient was discharged after the physical condition was improved. It's suggestied that clinicians should pay attention to rare complications to prevent missed diagnosis when treating other bromadiolone poisoning.. 溴敌隆是一种长效香豆素类抗凝类杀鼠剂，俗称"超级华法林"，其作用机制主要是抑制维生素K1环氧化物还原酶，影响凝血因子Ⅱ、Ⅶ、Ⅸ和Ⅹ的合成，致使机体凝血机能障碍，导致全身多脏器出血。本文报道一例溴敌隆中毒后导致消化道、腹腔出血，同时继发麻痹性肠梗阻的患者，给予输注血制品、补充维生素K1等治疗后，病情好转出院。提示临床医生在救治其他溴敌隆中毒时，要注意少见并发症，以免漏诊。.

Topics: 4-Hydroxycoumarins; Blood Coagulation Factors; Dicumarol; Hemorrhage; Humans; Intestinal Pseudo-Obstruction; Oxidoreductases; Rodenticides; Vitamin K 1; Warfarin

Limited data are available on the clinical course of patients with history of atrial fibrillation (AF) when admitted in an intensive care environment. We aimed to describe the occurrence of major adverse events in AF patients admitted to a stepdown care unit (SDU) and to analyse clinical factors associated with outcomes, impact of dicumarolic oral anticoagulant (OAC) therapy impact and performance of clinical risk scores in this setting.. Single-centre, observational retrospective analysis on a population of subjects with AF history admitted to a SDU. Therapeutic failure (composite of transfer to ICU or death) was considered the main study outcome. Occurrence of stroke and major bleeding (MH) was considered as secondary outcomes. The performance of clinical risk scores was evaluated.. A total of 1430 consecutive patients were enrolled. 194 (13.6%) reported the main outcome. Using multivariate logistic regression, age (odds ratio [OR]: 1.03, 95% confidence interval [CI]: 1.01-1.05), acute coronary syndrome (OR:3.10, 95% CI: 1.88-5.12), cardiogenic shock (OR:10.06, 95% CI: 5.37-18.84), septic shock (OR:5.19,95%CI:3.29-18.84), acute respiratory failure (OR:2.49, 95% CI: 1.67-3.64) and OAC use (OR: 1.61, 95% CI: 1.02-2.55) were independently associated with main outcome. OAC prescription was associated with stroke risk reduction and to both MH and main outcome risk increase. CHA. In critically ill AF patients admitted to a SDU, adverse outcomes are highly prevalent. OAC use is associated to an increased risk of therapeutic failure, clinical scores seem unhelpful in predicting stroke and MH, suggesting a highly individualized approach in AF management in this setting.

Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comorbidity; Critical Illness; Dicumarol; Female; Hemorrhage; Hospital Mortality; Hospital Units; Humans; Intensive Care Units; Logistic Models; Male; Multivariate Analysis; Patient Transfer; Respiratory Insufficiency; Retrospective Studies; Shock, Cardiogenic; Shock, Septic; Stroke

The safety of direct oral anticoagulants (DOACs) in oldest old patients with nonvalvular atrial fibrillation (NVAF) in daily clinical practice has not been systematically assessed. This study examined the safety of DOACs and dicumarol (a vitamin K antagonist) in NVAF geriatric patients.. Prospective study from January 2010 through June 2015, with follow-up through January 2016.. Geriatric medicine department at a tertiary hospital.. A total of 554 outpatients, 75 years or older, diagnosed of NVAF and starting oral anticoagulation.. The main outcome was bleeding, which was classified into major (including those life-threatening) and nonmajor episodes. Statistical analyses were performed with Cox regression.. A total of 351 patients received DOACs and 193 dicumarol. Patients on DOACs were older, with more frequent comorbidities, mobility limitation and disability in activities of daily living, as well as higher mortality, than those treated with dicumarol. The incidence of any bleeding was 19.2/100 person-years among patients on DOACs and 13.7/100 person-years on dicumarol; corresponding figures for major bleeding were 5.2 for those on DOACs, and 3.3 for those on dicumarol. In crude analyses, hazard ratios (95% confidence intervals) for any bleeding, and for mayor bleeding in patients on DOACs vs dicumarol were 1.60 (1.04-2.44) and 2.22 (0.88-5.59), respectively. Excess risk of bleeding associated with DOACs vs dicumarol disappeared after adjustment for clinical characteristics, so that corresponding figures were 1.19 (0.68-2.08) and 1.01 (0.35-2.93). Results did not vary across subgroups of high-risk patients.. In very old patients with NVAF, the higher risk of bleeding associated with DOACs vs dicumarol could be mostly explained by the worse clinical profile of patients receiving DOACs. Risk of bleeding was rather high, and warrants close clinical monitoring.

Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Chronic Disease; Comorbidity; Dabigatran; Dementia; Dicumarol; Disabled Persons; Follow-Up Studies; Hemorrhage; Humans; Mobility Limitation; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K

Topics: Anticoagulants; Dicumarol; Evidence-Based Medicine; Hemorrhage; Humans; Practice Guidelines as Topic; Vitamin K

Eight of 600 Holstein heifers and cows died after ingestion of sweet clover silage (Melilotus sp) that contained excessive concentrations of dicumarol caused by mold infestation. The cattle developed subcutaneous hemorrhages and bled from the vagina, became weak, were unable to move, and died. To the best of our knowledge, this is the first report of sweet clover poisoning in cattle from California and is discussed in light of previous findings in the Midwest and Canada. Sweet clover poisoning is caused by dicumarol, a fungal metabolite produced from substrates in sweet clover, and is a common livestock problem in the Northern Plains and Canada. Sweet clover poisoning should be considered in livestock animals with clinical evidence of hemostatic dysfunction, prolonged coagulation times, subcutaneous hemorrhages, and hemorrhagic abortions. Definite diagnosis of moldy sweet clover poisoning can be accomplished by analysis of serum and feed samples for dicumarol concentrations.

Topics: Animals; Anticoagulants; California; Cattle; Cattle Diseases; Dicumarol; Fabaceae; Female; Hemorrhage; Plant Poisoning; Plants, Medicinal; Silage

Sweet clover poisoning in cattle is caused by an anticoagulant (dicumarol) that is formed in moldy sweet clover hay. Previous experiments with vitamin K3 and vitamin K1 in therapy trials indicated that vitamin K1 was effective in reducing prothrombin times but vitamin K3 was not. As a possible alternative in the use of toxic sweet clover hays, vitamin K3 was evaluated to see if it would prevent hemorrhagic crises when fed to cattle consuming toxic sweet clover hay. Vitamin K3 levels of 0, 0.45, 4.5, 11, and 45 mg/kg body weight/day were fed to 173-235-kg steers consuming toxic (40-50 ppm dicumarol) sweet clover. The 45-mg K3/kg/day supplement was not palatable and had to be discontinued. The 0.45, 4.5, and 11-mg K3/kg/day supplements did not significantly reduce the prothrombin times as compared to the 0-mg K3/kg/day group.

Topics: Animals; Cattle; Cattle Diseases; Dicumarol; Food Additives; Hematocrit; Hemorrhage; Plant Poisoning; Prothrombin Time; Vitamin K

Topics: Adolescent; Aortic Valve; Bioprosthesis; Child; Dicumarol; Female; Follow-Up Studies; Heart Valve Diseases; Heart Valve Prosthesis; Hemodynamics; Hemorrhage; Humans; Male; Mitral Valve; Postoperative Complications; Prosthesis Design; Prosthesis Failure; Thromboembolism

Between November, 1970, and December, 1977, 932 consecutive patients received the standard Björk-Shiley prosthesis. Operative mortality was 4.6% for aortic valve replacement (AVR; N = 364), 5.1% for mitral valve replacement (MVR; N = 313); 11.3% for multiple valve replacement (N = 194), and 13.7% for valve replacement combined with coronary artery bypass grafting (CABG; N = 51). Factors influencing hospital mortality included type of valve replacement, age at operation, whether the valve replacement was done as an emergency, and year of implantation. Complete follow-up (mean, 3.7 years) was achieved in 95% of the survivors. Actuarial survival was 82% for AVR patients at 8 years, 83% for MVR patients at 7 years, 72% for multiple valve replacement patients at 7 years, and 76% for those who had valve replacement with CABG at 3 years. No significant difference in late survival was found between patients with mitral insufficiency alone (p greater than 0.2) or aortic insufficiency alone (p greater than 0.9) and those with stenotic lesions only. Thromboembolic complications occurred at an incidence of 1.17% per patient-year, and Dicumarol-induced hemorrhages occurred at an incidence of 2.11% per patient-year. Twelve out of 13 patients survived operation for prosthetic valve thrombosis, indicating that this complication is not as catastrophic as many believe. The incidence of reoperation in anticoagulated patients was 0.63% per patient-year. All of these results are compared with data from the recent literature.

Topics: Aged; Aortic Valve; Coronary Artery Bypass; Dicumarol; Follow-Up Studies; Heart Valve Prosthesis; Hemorrhage; Humans; Mitral Valve; Reoperation; Thromboembolism

Topics: Animals; Blood Coagulation; Blood Coagulation Disorders; Dicumarol; Factor X Deficiency; Factor XI Deficiency; Factor XIII Deficiency; Hemophilia B; Hemorrhage; Hemostasis; Heparin; Horse Diseases; Horses; Models, Biological

Topics: Adult; Dicumarol; Female; Hemoperitoneum; Hemorrhage; Humans; Middle Aged; Ovary; Rupture, Spontaneous

Quinton-Scribner shunts have been used as a reliable access to the blood-stream in 56 patients treated with intermittent hemodialysis in the years 1965-71. The mean age of 29 men and 27 women was 39 years. Two hundred and thirty-two cannulae showed a mean survival time of 11.2 months for 103 arterial cannulae and 9.0 months for 129 venous cannulae. 700 shunt clotting episodes occurred during 1157 patient months, i.e. 0.6 clotting episode/month. In 350 episodes where saline flushing could not remove the clot, the effect of treatment with streptokinase was considered evident in 79.7%. Shunt cannula infection was a common complication while aseptic cutaneous necrosis and bleeding from the cannulated vessel were seen less frequently. Both severe and less harmful bleeding episodes were seen as a complication of dicumarol therapy. The number of complications to streptokinase treatments was low. The advantages and disadvantages of the Quinton-Scribner shunt for hemodialysis are discussed.

Topics: Adolescent; Adult; Arteriovenous Shunt, Surgical; Blood Coagulation; Child; Dicumarol; Female; Fever; Hemorrhage; Humans; Male; Middle Aged; Osteonecrosis; Postoperative Complications; Renal Dialysis; Sodium Chloride; Staphylococcal Infections; Streptokinase; Surgical Wound Infection

The usefulness of assays for the rapid identification and determination of quantitative plasma levels of warfarin sodium and dicumarol is documented by the case histories of five patients: a man who accidentally took dicumarol for several weeks and developed an acute condition within the abdomen, a man who ingested 500 mg of warfarin sodium in a suicide attempt, a malingering nurse who surreptitiously took dicumarol, a nurse with warfarin intoxication who did not follow dosage prescription because of fear of developing thrombosis, and a woman with calf vein thrombosis who did not ingest the administered warfin sodium becausing of fear of developing bleeding. In every patient, the diagnosis of surreptitious ingestion or noningestion was suspected on the basis of the coagulation profile pattern. Confirmation of the disorder by the spectrophotometric assay enable the clinician to choose the appropriate course of action with speed and purpose.

Topics: Accidents, Home; Administration, Oral; Adult; Aged; Anticoagulants; Blood Coagulation Tests; Dicumarol; Female; Hemorrhage; Humans; Male; Malingering; Prothrombin Time; Sodium; Spectrophotometry, Ultraviolet; Warfarin

Topics: Adult; Aged; Coronary Disease; Dicumarol; Female; Hemorrhage; Humans; Male; Middle Aged

Topics: Anti-Bacterial Agents; Chloramphenicol; Dicumarol; Drug Interactions; Hemorrhage; Humans; Postoperative Complications; Surgical Procedures, Operative; Surgical Wound Infection

Topics: Abdominal Muscles; Aged; Anticoagulants; Dicumarol; Female; Hemorrhage; Humans; Myocardial Infarction

Topics: Animals; Dicumarol; Disease Models, Animal; Hemorrhage; Hemostasis; Heparin; Humans; Rats; Sodium Chloride; Stress, Psychological

Topics: Animals; Castration; Dicumarol; Estradiol; Female; Hemorrhage; Oxandrolone; Rats; Spironolactone; Steroids

Topics: Aged; Angiography; Anticoagulants; Blindness; Dicumarol; Eye Diseases; Fluoresceins; Hemorrhage; Humans; Intraocular Pressure; Male; Pulmonary Embolism; Retina; Retinal Degeneration; Ultrasonography

Topics: Animals; Ascorbic Acid; Ascorbic Acid Deficiency; Blood Coagulation Factors; Blood Platelet Disorders; Blood Platelets; Dicumarol; Factor VII; Glycine max; Hemorrhage; Hemostatics; Humans; Pedigree; Phospholipids; Plasma; Prothrombin; Prothrombin Time; Rabbits; Thrombocytopenia; Thromboplastin; Vitamin K; Vitamin K Deficiency

Topics: Abortion, Spontaneous; Adult; Dicumarol; Disseminated Intravascular Coagulation; Female; Hemorrhage; Humans; Personality Disorders; Pregnancy; Prothrombin Time; Spectrophotometry; Substance-Related Disorders; Vitamin K

Topics: Anemia, Neonatal; Blood Coagulation Factors; Dicumarol; Erythroblastosis, Fetal; Factor VIII; Female; Fibrinogen; Hemophilia A; Hemophilia B; Hemorrhage; Hepatitis A; Humans; Immunization, Passive; Immunoglobulins; Infant, Newborn; Infusions, Parenteral; Injections, Intravenous; Liver Diseases; Plasma; Pregnancy; Tetanus; Tissue Extracts

Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adult; Anticoagulants; Aspirin; Blood Coagulation Tests; Blood Platelets; Chlorthalidone; Collagen; Dicumarol; Epinephrine; Hematocrit; Hemorrhage; Humans; Male; Metabolism; Platelet Adhesiveness; Prothrombin Time; Sodium; Warfarin

Independent groups of rats were deprived of sleep and treated with the anticoagulant drugs phenylindanedione or dicoumarol for 1 to 8 days. These animals developed an extremely severe anemia which was accelerated by p-chlorophenylalanine. The red cell count and amount of hemoglobin decreased to half of normal values. No decrease occurred in animals subjected to any one single treatment. Histological examination indicated hemolysis, hypoplasia of hemopoietic organs, slight hemorrhage, but no evidence of stress. The severity of the anemia was inversely related to the amount of sleep permitted during sleep deprivation. This new syndrome demonstrates marked effects of sleep deprivation on both maturation and destruction of red blood cells. Depletion of serotonin by injection of parachlorophenylalanine blocked the increase in amount of brain waves of the type commonly seen in slow wave sleep but did not eliminate the production of these waves. This result is at variance with the theory that serotonin is the neurochemical responsible for the "priming" of slow wave sleep.

Topics: Anemia; Animals; Anticoagulants; Dicumarol; Drug Synergism; Electroencephalography; Fenclonine; Hemoglobins; Hemorrhage; Liver; Myocardium; Phenindione; Rats; Sleep Deprivation; Spleen

Topics: Administration, Oral; Animals; Body Weight; Depression, Chemical; Dicumarol; Hemorrhage; Male; Mice; Vitamin K

Topics: Animals; Castration; Dicumarol; Drug Interactions; Hemorrhage; Male; Prothrombin Time; Rats; Rats, Inbred Strains; Testosterone; Time Factors

Topics: Animals; Dicumarol; Female; Fetus; Hemorrhage; Hypoprothrombinemias; Mice; Pregnancy; Prothrombin; Prothrombin Time; Sodium Salicylate

Topics: Animals; Blood Transfusion; Dicumarol; Hemorrhage; Poisoning; Swine; Swine Diseases; Vitamin K

Topics: Adult; Antidepressive Agents; Anxiety Disorders; Dicumarol; Female; Hemorrhage; Humans; Hysteria; Malingering; Masochism; Obsessive-Compulsive Disorder; Psychopathology; Tranquilizing Agents; Vitamin K

Topics: Anemia, Hemolytic, Congenital; Anemia, Neonatal; Blood Coagulation Factors; Blood Transfusion; Chlorothiazide; Dicumarol; Female; Glucosephosphate Dehydrogenase Deficiency; Hemoglobinopathies; Hemophilia A; Hemorrhage; Humans; Infant, Newborn; Iron; Liver; Pregnancy; Thrombocytopenia; Vitamin K; Vitamin K Deficiency Bleeding

Topics: Dicumarol; Hemorrhage; Hernia, Inguinal; Humans; Male; Middle Aged; Spermatic Cord; Testis

Topics: Adult; Age Factors; Aged; Aprotinin; Dicumarol; Female; Hemorrhage; Humans; Male; Middle Aged; Peritonitis; Postoperative Complications; Pulmonary Embolism; Sex Factors; Wound Healing

Topics: Adenine Nucleotides; Adrenochrome; Animals; Dicumarol; Hemorrhage; Heparin; Male; Mice; Models, Theoretical; Nucleosides

Topics: Animals; Barbiturates; Dicumarol; Hemorrhage; Male; Pentobarbital; Prothrombin Time; Rats; Sleep

Topics: Aged; Breast Diseases; Breast Neoplasms; Dicumarol; Female; Gangrene; Hemorrhage; Humans; Middle Aged; Necrosis; Pulmonary Embolism; Thrombophlebitis

Topics: Animals; Anticoagulants; Chlorides; Dicumarol; Epinephrine; Female; Hemorrhage; Histamine H1 Antagonists; In Vitro Techniques; Metals; Rats; Sympatholytics; Thrombosis

Topics: Acenocoumarol; Adult; Aged; Anticoagulants; Blood Coagulation Tests; Cardiovascular Diseases; Dicumarol; Female; Hemorrhage; Heparin; Humans; Hypertension; Male; Middle Aged; Phenindione

Topics: Aged; Dicumarol; Gallbladder Diseases; Hemorrhage; Humans; Male

Topics: Dicumarol; Duodenal Diseases; Gastrointestinal Hemorrhage; Geriatrics; Hematuria; Hemorrhage; Hypoprothrombinemias; Ileum; Intestinal Obstruction; Intestine, Small; Jejunum; Pathology; Radiography; Surgical Procedures, Operative; Toxicology; Warfarin

Topics: Adenoma; Adenoma, Chromophobe; Anticoagulants; Cerebral Angiography; Cerebral Hemorrhage; Dicumarol; Hemorrhage; Humans; Pathology; Pituitary Neoplasms; Toxicology

Topics: Adrenal Gland Diseases; Aged; Dicumarol; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged

Topics: Adult; Dicumarol; Female; Hemorrhage; Humans; Ovarian Diseases; Phlebitis

Topics: Agar; Animals; Carrageenan; Croton Oil; Dicumarol; Female; Hemorrhage; Heparin; Injections, Subcutaneous; Iron; Rats; Skin; Skin Diseases

Topics: Anaphylaxis; Dicumarol; Fibrinolysin; Hemorrhage; Heparin; Hepatitis; Hepatitis B virus; Humans; Myocardial Infarction; Pulmonary Embolism; Thromboembolism; Thrombophlebitis; Toxicology

Topics: Anticoagulants; Breast Diseases; Dicumarol; Electrocardiography; Female; Gangrene; Hemorrhage; Humans; Lanatosides; Pregnancy; Puerperal Disorders; Rifamycins; Thrombophlebitis; Toxicology

Topics: Anticoagulants; Coronary Disease; Dicumarol; Embolism; Ethyl Biscoumacetate; Hemorrhage; Humans; Postoperative Complications; Prothrombin Time; Thrombophlebitis; Toxicology; Warfarin

Topics: Appendicitis; Diagnosis, Differential; Dicumarol; Hemorrhage; Myocardial Infarction; Peritoneal Cavity; Surgical Procedures, Operative; Toxicology

Topics: Dicumarol; Female; Hemorrhage; Humans; Necrosis; Puerperal Disorders; Skin Diseases; Thrombophlebitis; Toxicology

Topics: Aminocaproates; Aminocaproic Acid; Anticoagulants; Biomedical Research; Chloroform; Dicumarol; Dogs; Hemophilia A; Hemorrhage; Pharmacology; Research; Thromboplastin

Topics: Adrenalectomy; Adrenocorticotropic Hormone; Dicumarol; Hemorrhage; Heparin; Insulin; Pharmacology; Phenindione; Phosphorus Isotopes; Rabbits; Rats; Research; Reserpine; Seizures; Serotonin; Sodium Chloride; Stress, Physiological; Thrombocytopenia; Toxicology

Topics: Adrenocorticotropic Hormone; Animals; Corticosterone; Cortisone; Dicumarol; Growth Hormone; Hemorrhage; Human Growth Hormone; Hydrocortisone; Lagomorpha; Pharmacology; Phenindione; Prothrombin; Prothrombin Time; Rabbits; Research

Topics: Coumarins; Dicumarol; Drug Therapy; Duodenal Ulcer; Gastric Mucosa; Gastrointestinal Hemorrhage; Geriatrics; Hemorrhage; Heparin; Humans; Myocardial Infarction; Pathology; Peptic Ulcer Hemorrhage; Stomach Ulcer

Topics: Cardiac Tamponade; Colonic Neoplasms; Dicumarol; Eye; Female; Gastrointestinal Hemorrhage; Geriatrics; Hematoma; Hemoperitoneum; Hemorrhage; Humans; Ileum; Intestinal Obstruction; Ovarian Follicle; Pulmonary Embolism; Surgical Procedures, Operative; Toxicology

Topics: Anticoagulants; Dicumarol; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intestinal Obstruction

Topics: Dicumarol; Hemorrhage; Humans; Mental Disorders; Stress, Physiological

Topics: Blood Coagulation; Dicumarol; Hemorrhage; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Milk

Topics: Anticoagulants; Atrial Fibrillation; Dicumarol; Hemorrhage; Humans; Lung; Mitral Valve Stenosis; Pathology; Pharmacology; Toxicology

Topics: Dicumarol; Disease; Gastrointestinal Hemorrhage; Hemorrhage; Intestinal Diseases; Intestine, Small; Necrosis

Topics: Adrenal Gland Diseases; Adrenal Glands; Blood Coagulation; Dicumarol; Health Services; Hemorrhage; Humans

Topics: Anticoagulants; Corpus Luteum; Dicumarol; Female; Hemoperitoneum; Hemorrhage; Humans; Rupture

Topics: Adrenal Cortex Hormones; Animals; Dicumarol; Hemorrhage; Hormones; Pituitary Diseases; Pituitary Gland; Pituitary Gland, Anterior; Prothrombin Time; Rats

Topics: Dicumarol; Hemorrhage; Humans; Kidney; Kidney Diseases

Topics: Dicumarol; Hemorrhage; Humans; Thrombosis

Topics: Adrenal Gland Diseases; Adrenal Glands; Dicumarol; Hemorrhage; Humans; Myocardial Infarction

Topics: Adhesives; Anticoagulants; Dicumarol; Hemorrhage; Humans; Pericardial Effusion; Pericarditis; Pericarditis, Constrictive; Pericardium

Topics: Dicumarol; Hemorrhage; Humans; Tooth Extraction

Topics: Coumarins; Dicumarol; Disease Management; Hemorrhage

Topics: Administration, Cutaneous; Coumarins; Dicumarol; Gangrene; Hemorrhage; Necrosis; Skin

Topics: Anticoagulants; Dicumarol; Hemorrhage; Heparin; Humans; Larynx; Otolaryngology; Pharynx

Topics: Coumarins; Dicumarol; Hemorrhage; Humans; Myocardial Infarction; Paraplegia; Spinal Cord

Topics: Coagulants; Coumarins; Dicumarol; Gangrene; Hemorrhage; Humans; Necrosis; Skin

Topics: Coumarins; Dicumarol; Hemorrhage; Humans; Paraplegia; Spinal Cord; Spinal Cord Vascular Diseases

Topics: Antifibrinolytic Agents; Coumarins; Dicumarol; Hemorrhage; Naphthoquinones; Poisoning; Retinoids; Vitamin K; Vitamin K 1

Topics: Anticoagulants; Antifibrinolytic Agents; Dicumarol; Hemorrhage; Hemostatics; Humans; Naphthoquinones; Vitamin K

Topics: Coumarins; Dicumarol; Hemorrhage; Self Medication

Topics: Abdomen; Acute Disease; Coumarins; Dicumarol; Gastrointestinal Diseases; Hemorrhage

Topics: Coumarins; Dicumarol; Hematoma; Hemorrhage; Humans; Mouth; Oral Hemorrhage

Topics: Coumarins; Dicumarol; Hemorrhage; Humans; Inorganic Chemicals

Topics: Dicumarol; Hemorrhage

Topics: Dicumarol; Hemorrhage; Syndrome; Tolonium Chloride; Toluidines

Topics: Coumarins; Dicumarol; Hemorrhage; Humans

Topics: Abdominal Wall; Coumarins; Dicumarol; Hemorrhage; Humans

Topics: Dicumarol; Hemorrhage; Humans

Topics: Dicumarol; Hemorrhage; Humans

Topics: Dicumarol; Hemorrhage; Prothrombin Time

Topics: Autopsy; Cause of Death; Dicumarol; Hemorrhage; Humans

Topics: Dicumarol; Hemorrhage

Topics: Cardiovascular Diseases; Dicumarol; Heart; Hemorrhage; Infarction; Minnesota; Myocardial Infarction; Pericardial Effusion; Pericardium

Topics: Dicumarol; Hemorrhage

Topics: Coumarins; Dicumarol; Hemorrhage

Topics: Dicumarol; Hemorrhage